| abstract |
The present invention relates to a short-chain insulin analogue conjugate having a single-chain insulin analog, a non-peptidyl polymer, and an immunoglobulin Fc region covalently linked to each other, thereby improving durability and stability in vivo. The short-chain insulin analogue conjugate of the present invention relates to a breakthrough short-chain insulin analogue conjugate that exhibits insulin-like activity in vivo and has a markedly increased half-life in blood and does not induce hypoglycemia, which is a disadvantage of insulin treatment. |